Mobile

A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000597-31

A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses of 5-10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease patients with transfusional hemosiderosis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Evaluate the long-term safety and tolerability profile of ICL670 in sickle cell disease patients with transfusional iron overload requiring chelation therapy

Critère d'inclusion

  • Sickle cell disease patients with transfusional hemosiderosis

Liens